Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -839.37% is 39% above its 4-year average of -1371.86%, near the high end of its 4-year range (-20735.35%–2181.04%).
455.62% below its 12-month average of -151.07%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -1358.67%.
EBITDA MARGIN
-839.37%
EBITDA MARGIN AVG TTM
-151.07%
EBITDA MARGIN AVG 3Y
-1217.02%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-455.62%
CURRENT VS 3Y AVG
+31.03%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Optimi Health Corp.
Market Cap
$13.48M
EBITDA Margin
-839.37%
TTM Avg
-151.07%
3Y Avg
-1217.02%
5Y Avg
N/A
Market Cap
$13.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.73M
EBITDA Margin
-988.11%
TTM Avg
-1002.20%
3Y Avg
-1043.90%
5Y Avg
-1194.77%
Market Cap
$14.11M
EBITDA Margin
-23.39%
TTM Avg
-215.41%
3Y Avg
-426.39%
5Y Avg
-612.06%
Market Cap
$14.11M
EBITDA Margin
-855.47%
TTM Avg
-475.86%
3Y Avg
-335.10%
5Y Avg
-307.83%
Market Cap
$12.62M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Optimi Health Corp. (OPTH) | $13.48M | -839.37% | -151.07% | -1217.02% | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.37M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.73M | -988.11% | -1002.20% | -1043.90% | -1194.77% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.81M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.11M | -23.39% | -215.41% | -426.39% | -612.06% |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | -855.47% | -475.86% | -335.10% | -307.83% |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.62M | -34.02% | -37.67% | -64.98% | -56.41% |
| Lantern Pharma Inc. (LTRN)vs › | $12.25M | N/A | N/A | N/A | N/A |
Gross Margin
-486.4%
EBITDA Margin
-839.4%
Operating Margin
-1062.3%
Net Margin
-3972.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1358.67% |
| 2026-03-31 | -1135.81% |
| 2025-09-30 | 2181.04% |
| 2025-06-30 | -290.84% |
| 2025-03-31 | -1249.07% |
| 2024-12-31 | -399.36% |
| 2024-09-30 | -2296.67% |
| 2024-06-30 | -673.18% |
| 2024-03-31 | -1360.73% |
| 2023-12-31 | -939.28% |
| 2023-09-30 | -6094.12% |
| 2023-06-30 | -2466.62% |
| 2023-03-31 | 307.49% |
| 2022-12-31 | -1362.63% |
| 2022-09-30 | -3136.40% |
| 2022-06-30 | -2844.27% |
| 2022-03-31 | -20735.35% |
